An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

NCT02394834 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

757

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
DRUG: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab

Sponsor

Takeda